Diprovocim

Overview

Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells ( EC 50 =110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages ( EC 50 =1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pain | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-123942
• CAS No.: 2170867-89-5
• Molecular Formula: C56H56N6O6
• Molecular Weight: 909.08
• Purity: 98.82%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (2.75 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source